Efficacy analysis of bortezomib-based chemotherapy for 28 cases with multiple myeloma

VernacularTitle:硼替佐米联合化疗治疗多发性骨髓瘤28例疗效分析
Author: Yuebo LIU ; Feng GAO ; Jin YAO
Publication Type:Journal Article
Keywords: Multiple myeloma; Bortezomib; Treatment outcome
From: Journal of Leukemia & Lymphoma 2012;21(9):537-539
CountryChina
Language:Chinese
Abstract: Objective To examine the efficacy and adverse reactions of bortezomib-based chemotherapy in treatment of multiple myeloma (MM).Methods Twenty-eight patients with multiple myeloma received a joint chemotherapy containing bortezomib.The efficacy was determined according to EBMT criteria.Results 28 patients received the chemotherapy,20 patients were newly diagnosed and 8 patients were relapsed or refractory.25 patients can be evaluateed efficacy.The total response rate was 100 ％ (25/25),consisting of 5 patients with complete response (CR),10 patients with almost complete remission (nCR),10 patients with partial remission (PR).The main side effects include peripheral neuropathy,thrombocytopenia,gastrointestinal disorders and viral infections.These side effects were improved by symptomatic treatment and generally did not affect the treatment.Conclusion For the newly diagnosed and relapsed or refractory multiple myeloma cases,bortezomib-based chemotherapy is a safe and effective therapeutic drug with rapid onset,high treatment response rate,and adverse reaction can be tolerated.